We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $113.03 in the latest trading session, marking a -2.73% move from the prior day. This change lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 0.33%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 5% in the past month. In that same time, the Medical sector gained 1.92%, while the S&P 500 gained 4.93%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on August 7, 2025. The company's earnings per share (EPS) are projected to be $1.96, reflecting a 2.49% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.95 billion, down 0.1% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.02 per share and revenue of $28.67 billion. These totals would mark changes of +73.59% and -0.28%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.37% higher. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 14.48 right now. This represents a discount compared to its industry average Forward P/E of 20.33.
One should further note that GILD currently holds a PEG ratio of 0.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.75 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Gilead Sciences (GILD - Free Report) closed at $113.03 in the latest trading session, marking a -2.73% move from the prior day. This change lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 0.33%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 5% in the past month. In that same time, the Medical sector gained 1.92%, while the S&P 500 gained 4.93%.
The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on August 7, 2025. The company's earnings per share (EPS) are projected to be $1.96, reflecting a 2.49% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.95 billion, down 0.1% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.02 per share and revenue of $28.67 billion. These totals would mark changes of +73.59% and -0.28%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.37% higher. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 14.48 right now. This represents a discount compared to its industry average Forward P/E of 20.33.
One should further note that GILD currently holds a PEG ratio of 0.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.75 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.